Literature DB >> 18313561

Meta-analyses of chronic disease trials with competing causes of death may yield biased odds ratios.

Michael T Koller1, Theo Stijnen, Ewout W Steyerberg, Jacobus Lubsen.   

Abstract

OBJECTIVE: To study the odds ratio (OR) as measure of treatment effect in the context of mutually exclusive causes of death. STUDY DESIGN AND
SETTING: As example we consider meta-analyses of randomized trials of implantable cardioverter defibrillator implantation (ICD). We compare the pooled OR to the pooled cause-specific hazard ratio (HR) for each of the mutually exclusive outcomes "sudden cardiac death" (SCD) and "death other than SCD."
RESULTS: The pooled OR and cause-specific HR for the reduction of SCD are similar (0.43 and 0.44, respectively) for nine included trials. However, the OR erroneously presumes a potential trend toward an adverse effect of the ICD on "death other than arrhythmia" (OR 1.11 [0.84-1.45]), whereas such an effect is small with the cause-specific HR (HR 1.03 [0.79-1.32]). In general, it is shown that a spurious association of treatment with "other death" may be seen when a substantial number of death from the cause of interest is postponed.
CONCLUSION: The OR should be used with caution to study effects of treatment on mutually exclusive causes of death. Practically this concern applies primarily to meta-analysis where the use of the cause-specific HR, whenever available, is recommended.

Entities:  

Mesh:

Year:  2007        PMID: 18313561     DOI: 10.1016/j.jclinepi.2007.05.009

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  4 in total

1.  Cancer mortality in patients with psychiatric diagnoses: a higher hazard of cancer death does not lead to a higher cumulative risk of dying from cancer.

Authors:  Ng Chong Guan; Fabian Termorshuizen; Wijnand Laan; Hugo M Smeets; Nor Zuraida Zainal; René S Kahn; Niek J De Wit; Marco P M Boks
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-10-27       Impact factor: 4.328

2.  Competing risks and the clinical community: irrelevance or ignorance?

Authors:  Michael T Koller; Heike Raatz; Ewout W Steyerberg; Marcel Wolbers
Journal:  Stat Med       Date:  2011-09-23       Impact factor: 2.373

3.  Initially fewer bloodstream infections for allogeneic vs. autologous stem-cell transplants in neutropenic patients.

Authors:  S Hieke; H Bertz; M Dettenkofer; M Schumacher; J Beyersmann
Journal:  Epidemiol Infect       Date:  2012-03-07       Impact factor: 4.434

4.  Understanding competing risks: a simulation point of view.

Authors:  Arthur Allignol; Martin Schumacher; Christoph Wanner; Christiane Drechsler; Jan Beyersmann
Journal:  BMC Med Res Methodol       Date:  2011-06-03       Impact factor: 4.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.